Phio Pharmaceuticals Corp. financial data

Symbol
PHIO on Nasdaq
Location
King Of Prussia, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 824% % 80%
Debt-to-equity 14% %
Return On Equity -86% % 36%
Return On Assets -76% % 30%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10,764,428 shares 920%
Common Stock, Shares, Outstanding 5,784,770 shares 504%
Entity Public Float $3,200,000 USD -44%
Common Stock, Value, Issued $1,000 USD
Weighted Average Number of Shares Outstanding, Basic 5,468,584 shares 452%
Weighted Average Number of Shares Outstanding, Diluted 4,794,857 shares 840%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $4,126,000 USD 13%
General and Administrative Expense $4,234,000 USD 11%
Operating Income (Loss) $8,360,000 USD -9.8%
Nonoperating Income (Expense) $143,000 USD 110%
Net Income (Loss) Attributable to Parent $7,953,000 USD -7.2%
Earnings Per Share, Basic -4 USD/shares 82%
Earnings Per Share, Diluted -5 USD/shares 83%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $10,705,000 USD 99%
Assets, Current $11,493,000 USD 96%
Property, Plant and Equipment, Net $12,000 USD 1100%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $0 USD -100%
Assets $11,505,000 USD 96%
Accounts Payable, Current $516,000 USD 180%
Employee-related Liabilities, Current $31,000 USD -86%
Accrued Liabilities, Current $1,150,000 USD 56%
Liabilities, Current $1,206,000 USD -21%
Operating Lease, Liability, Noncurrent $0 USD
Liabilities $1,666,000 USD
Retained Earnings (Accumulated Deficit) $152,683,000 USD -5.5%
Stockholders' Equity Attributable to Parent $9,839,000 USD 99%
Liabilities and Equity $11,505,000 USD 96%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,275,000 USD 37%
Net Cash Provided by (Used in) Financing Activities $9,173,000 USD
Net Cash Provided by (Used in) Investing Activities $2,000 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 5,784,770 shares 504%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,775,000 USD 129%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD -100%
Deferred Tax Assets, Valuation Allowance $337,000 USD -87%
Deferred Tax Assets, Gross $350,000 USD -86%
Operating Lease, Liability $0 USD -100%
Payments to Acquire Property, Plant, and Equipment $2,000 USD
Property, Plant and Equipment, Gross $308,000 USD -73%
Operating Lease, Liability, Current $0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -106%
Deferred Tax Assets, Operating Loss Carryforwards $26,000 USD -97%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares -90%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $0 USD -100%
Additional Paid in Capital $162,521,000 USD 8.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $0 USD -100%
Share-based Payment Arrangement, Expense $113,000 USD 117%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%